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Several noncovalent complexes of large fragments of human GH, which are less active than native human 
GH in stimulating glucose metabolism in adipose tissue of hypophysectomized rats, were tested for their 
ability to compete with 12s I-iodinated human GH for specific binding to isolated adipocytes of hypophysecto- 
mized rats. The complexes tested were A (residues 1-134 + residues 141-191; S-carbamidomethylated), B 
(residues 1-134 + residues 135-191; S-carbamidomethylated) and C (residues 1-134 + residues 135-191; 
S-carboxymethylated). When compared to native human GH, the complexes were less active in competing 
with 12sI-iodinated human GH for specific binding to adipocytes, and their order of potency in the binding 
assay (A > B > C) was similar to that of their respective activities in stimulating glucose metabolism in 
isolated adipose tissue of hypophysectomized rats. 
Pituitary GH has several seemingly unrelated 
biological activities, including growth-promoting, 
diabetogenic and insulin-like activities and in the 
case of primate GHs, lactogenic activity. Recent 
work in our laboratory [1-3] on the structure- 
function relationships of human GH has demon- 
strated that noncovalent complexes of large frag- 
ments of human G H  have markedly altered activ- 
ity profiles, when compared to native human GH, 
and more particularly that the various activities 
have been altered in a nonparallel fashion. With 
all of the fragment complexes studied to date, 
insulin-like activity, as assessed by the in vitro 
ability of the substance to stimulate glucose up- 
take and metabolism by isolated adipose tissue of 
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Abbreviations: Complexes A, B and C refer to preparations 
Dal, R22079 and RCM-TD-hGH, respectively, from Refs. 2 
and 3. 
hypophysectomized rats, is attenuated. However, 
the fragment complexes vary in the extent to which 
their insulin-like activity is attenuated. Since it has 
been shown that there are specific binding sites for 
human GH on isolated rat adipocytes [4-6], the 
availability of human GH fragment complexes 
having varying degrees of insulin-like activity pro- 
vided an opportunity to study the correlation be- 
tween their insulin-like activity on isolated adipose 
tissue and their ability to complete with I25I- 
iodinated human G H  for specific binding to iso- 
lated adipocytes of hypophysectomized rats. It has 
not yet been possible to demonstrate in vitro ef- 
fects of G H  on isolated adipocytes from hypo- 
physectomized rats [7,8], probably because the cells 
are altered in some way during the isolation proce- 
dure. Therefore, no attempt was made in this 
study to measured effects of the complexes on the 
metabolism of the cells used in the binding studies. 
A highly purified human G H  (A-type; 2.1 
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I .U. /mg)  used for preparation of the radioactive 
ligand and as the reference standard in the binding 
assay was isolated as previously described [9]. 
125I-Iodinated human GH was prepared from this 
hormone by iodinating it with 1251 by the 
lactoperoxidase method of Thorell and Johansson 
[10]. Three human GH fragment complexes were 
studied. Complex A, consisting of a stable nonco- 
valent complex of residues 1-134 and 141-191, 
was isolated from plasmin-digested S-carba- 
midomethylated human GH [11]. Complex A has 
growth-promoting [1] and diabetogenic [12] activ- 
ity equivalent to that of native human GH, whereas 
its lactogenic activity is enhanced [1] and its in- 
sulin-like activity is about 30% that of the native 
hormone [1,13]. Complex B, consisting of a nonco- 
valent complex of residues 1-134 and 135-191, 
was produced by noncovalent complementation of 
S-carbamidomethylated human GH peptides 
1-134 and 135-191 [3]. It has approx. 35% of the 
growth-promoting activity of human GH, full di- 
abetogenic activity, whereas its insulin-like activity 
is only about 20% that of native human GH [3]. 
Complex C, consisting of a stable complex of 
residues 1-134 and 135-191, was produced by 
digesting human GH with thrombin and then re- 
ducing and S-carboxymethylating its disulfide 
bridges [2]. This complex has approx. 10% of the 
growth-promoting activity of human GH, full 
lactogenic activity, but its insulin-like activity is 
only about 5% that of the native hormone. 
Isolated adipocytes were prepared from the epi- 
didymal fat pads of male hypophysectomized rats 
of the Sprague-Dawley strain (90-100 g) from the 
Charles River Breeding Laboratories, Wilmington, 
MA. The animals were maintained on a high 
carbohydrate diet [14] for 4 weeks before being 
used in experiments. The rats were killed by de- 
capitation, and the epididymal fat pads were re- 
moved, minced and incubated with collagenase 
(2 mg/ml;  Type I, Worthington, Freehold, N J) in 
Krebs-Ringer bicarbonate buffer containing glu- 
cose (1 mM) and bovine serum albumin (1%, w/v)  
for 60 min at 37°C, according to the method of 
Rodbell [15]. The cells were washed four times 
with buffer without collagenase and then resus- 
pended and preincubated for 3 h at 37°C, since 
preincubation of the cells has been shown to in- 
crease their ability to bind ~25I-iodinated human 
G H  [16]. After preincubation, the cells were washed 
once, and 1.8-ml aliquots of the cell suspension 
( a p p r o x .  10 6 cells) were added to siliconized scin- 
tillation vials containing 0.1 ml 125 I-iodinated hu- 
man GH (2 4 ng; 200000 cpm; spec. act. of 
100-150 /xCi//~g) and 0.1 ml buffer containing 
various concentrations of human GH (2-5000 
ng/ml) ,  Complex A (10-5000 ng/ml),  Complex B 
(40-5000 ng/ml)  or Complex C (t00-5000 
ng/ml).  Incubation was carried out for 2 h at 
37°C. Triplicate 300-~1 aliquots of each cell sus- 
pension were then centrifuged through dinon- 
ylphthalate oil to separate the cells from their 
suspension buffer as described by Gliemann et al. 
[17]. The cell layer was excised and counted in an 
autogamma scintillation counter. Specific binding 
was determined by subtracting cell-bound radioac- 
tivity obtained in the presence of 5000 ng/ml  of 
unlabeled human GH from total cell-bound radio- 
activity. Total binding was 2-3% of the total ra- 
dioactivity in the incubation mixture, and non- 
specific binding was 0.6% of total binding. Values 
are expressed as percent of total cpm specifically 
bound per mg of extractable lipid, determined 
according to Gliemann [18]. 
The ability of native human GH and the vari- 
ous fragment complexes to compete with 1251- 
iodinated human G H  for specific binding to iso- 
lated adipocytes of hypophysectomized rats is 
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Fig. 1. I251-Iodinated human HG ([125I]iodo-hGH) binding to 
isolated adipocytes in the presence of various concentrations of 
human  GH (*),  Complex A (×) ,  Complex B (©) and Com- 
plex C (e). Values are expressed as percent of total specific 
[1251]iodo-gGH binding and are given as means +_ S.E. of three 
separate experiments. 
shown in Fig. 1. It can be seen that, in each case, 
competit ion was concentration-dependent and that 
the complexes were considerably less active than 
native human GH in competing with ~25 I-iodinated 
human GH for binding to the cells. The concentra- 
tion of human GH required to inhibit binding by 
50% ( B / B  o = 0.5) was 9.2 _+ 0.9 n g / m l  (mean _+ 
S.E. of three expeiiments).  In contrast, the con- 
centration of Complex A required to inhibit bind- 
ing by 50% was 67.4 + 6.8 ng /ml ,  198 + 14 n g / m l  
for Complex B and 961 _+ 96 n g / m l  for Complex 
C. 
These findings suggest that there is some corre- 
lation between the insulin-like activity of the 
several human GH fragment complexes tested and 
their ability to bind to adipocytes. All were less 
active than native human GH in vitro in stimulat- 
ing glucose metabolism in isolated adipose tissue 
of  hypophysectomized rats [1-3], and each was 
less effective than native human GH in competing 
with 125I-iodinated human GH for binding to iso- 
lated adipocytes of  hypophysectomized rats, their 
order of estimated potency in stimulating glucose 
metabolism in adipose tissue (A > B > C) being 
similar to their order of activity in the binding 
assay. 
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